Breaking Finance News

Trevena Inc (NDAQ:TRVN) stock price target bumped down to $7.00, released a ratings update earlier today by H.C. Wainwright

H.C. Wainwright bumped down the target of Trevena Inc (NDAQ:TRVN) to $7.00 stating a potential upside of 2.57%.

Boasting a price of $1.96, Trevena Inc (NDAQ:TRVN) traded -3.27% lower on the day. With the last close down -13.88% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. TRVN has recorded a 50-day average of $2.49 and a two hundred day average of $2.75. Trade Volume was up over the average, with 1,485,513 shares of TRVN changing hands over the typical 497,832

Performance Chart

Trevena Inc (NDAQ:TRVN)

With a total market value of $0, Trevena Inc has with a one year low of $2.15 and a one year high of $8.00 .

A total of 10 analysts have released a research note on TRVN. 4 brokerages rating the stock a strong buy, 6 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $14.55.

Brief Synopsis On Trevena Inc (NDAQ:TRVN)

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *